Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

Expansion of collaboration with Rett Syndrome Research Trust ... Net cash used in operating activities during the full year ended December 31, 2024 was € 36.4 million, compared to € 21.5 ...

Our growing discovery pipeline, now including CNS applications, leading intellectual property portfolio, and strategic partnerships - such as our $3.9 billion collaboration with Eli Lilly and ...

ProQR Therapeutics (PRQR) announced an expansion of its collaboration with the Rett Syndrome Research Trust ... Net cash used in operating activities during the three-month period ended September ...

TRUMBULL, Conn., March 13, 2025 (GLOBE NEWSWIRE) -- The Rett Syndrome Research Trust (RSRT), the organization working to cure Rett syndrome, is pleased to announce that Amy Gilliland, President of ...

Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which evaluates the safety and efficacy of leriglitazone ...